Navigation Links
Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide
Date:2/19/2008

NUTLEY, N.J., Feb. 19 /PRNewswire/ -- In response to recent media reports, Roche would like to reaffirm that there is ample supply of Tamiflu(R) (oseltamivir phosphate) antiviral medication for the 2007-2008 flu season, and that physicians and patients can feel confident the drug is on hand if flu strikes.

Some news reports have indicated "shortages" of the product at retail, but Roche has special measures in place to ensure that Tamiflu is readily available. If a pharmacy runs low due to high demand during peak flu season, and they can't get product from their servicing wholesaler(s), they can call 800-526-0625 and have Tamiflu delivered within 24 hours.

Due to widespread flu activity throughout the U.S., there has been an increase in the number of prescriptions being written for Tamiflu during the past few weeks. For the week ending February 9, the Centers for Disease Control and Prevention (CDC) cited 49 states reporting either widespread or regional flu activity.

The CDC web site suggests a "Take 3" approach against flu:

1. Take time to get a vaccine.

2. Take everyday actions to stop germs.

3. Take antiviral drugs if your doctor says you need them.

The CDC recommends that antiviral medications oseltamivir (Tamiflu) or zanamivir (Relenza(R)) can be used for the treatment and prevention of flu in the U.S. this season.

Tamiflu is a prescription antiviral medication that attacks the flu virus at its source, so patients can get better faster. Tamiflu is available as a capsule or liquid suspension formula, both of which are in sufficient supply. For optimal effectiveness, Tamiflu must be taken within 48 hours of the onset of flu symptoms, which include sore throat, extreme fatigue and sudden high fever. If patients experience these symptoms, they should contact a physician for accurate diagnosis and treatment, even if they have been vaccinated.

Tamiflu is Effective Against Seasonal Flu

Tamiflu is designed to be effective against all A and B strains of influenza. The CDC reported Friday that there are three primary viral types circulating in the U.S. this year -- two A strains (H1N1 and H3N2) and numerous B strains. The A strain H3N2 is the predominant virus for the season overall, and is typically associated with more severe illness.

The vaccine is not optimally matched to the H3N2 or the B viruses, according to the CDC report. The vaccine does appear to be well-matched against the H1N1. During this season, there has been a small increase observed in the number of H1N1 viruses resistant to Tamiflu, but no resistance has been identified among the H3N2 and B viruses. Tamiflu is not a substitute for an annual flu shot.

For more details and full prescribing information, please visit http://www.tamiflu.com.


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. As depression symptoms improve with antidepressants, hopelessness can linger
2. Optimal band imaging with endoscopy facilitates the diagnosis of depressed-type early gastric cancer
3. American Chemical Societys Weekly PressPac -- Feb. 13, 2008
4. Cleveland Clinic Press Consumer Health Book Empowers and Gives Hope to People with Epilepsy
5. Blood pressure drug may have added benefit
6. Oncoproteins double-team and destroy vital tumor-suppressor
7. Male births are more likely to reduce quality of life and increase severe post-natal depression
8. Airplane Noise Boosts Blood Pressure Even During Sleep
9. Cleveland Clinic Press Releases Book About a Surgeons Mission to Perform the Worlds First Full Face Transplant
10. High blood pressure worsening in all states for women; begins to stagnate for men
11. Most With High Blood Pressure Dont Follow Recommended Diet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Yisrayl Hawkins, ... focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement ... current generation. He explains that the Bible details the current times so plainly ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head Over Heels’ ... February 12th. Ms. Esparza qualified into this prestigious status after winning the ... Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in the nation ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to the La Gorce Country Club in Miami Beach to host its ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... and uncertainty in clinical trials, today announced that Premier Research, a leading clinical ... solution. , Clinical trials are becoming increasingly complex, due in part to an ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Oesophageal ... their offering. ... The latest research Oesophageal Cancer Drugs Price Analysis and Strategies - ... Cancer market. The research answers the following questions: ... Oesophageal Cancer and their clinical attributes? How are they positioned in ...
(Date:2/23/2017)... VALLEY COTTAGE, New York , February 23, 2017 ... to health implications arising from increasing caseload for varicose ... cases recorded across the globe are prompting the adoption ... A latest study on global endovenous laser therapy ... growing attention towards aftereffects of lifestyle choices and consequences ...
Breaking Medicine Technology: